Estimated life expectancy of Parkinson's patients compared with the UK population

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 12, 2007, Pages 1304-1309

  Ishihara, Lianna S ^b   Cheesbrough, Anne ^c   Brayne, Carol ^b   Schrag, Anette ^a,d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; TIME OF DEATH; UNITED KINGDOM; WESTERN EUROPE;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; FEMALE; GREAT BRITAIN; HUMANS; LEVODOPA; LIFE EXPECTANCY; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; SEX DISTRIBUTION;

EID: 36849018986     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.100107     Document Type: Article

References (53)

1. Diamond SG, Markham CH. Present morality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J Neural Transm 1976;38:259-69.
2. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311:1602-7.
3. DiRocco A, Molinari SP, Kollmeier B, et al. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol 1996;69:3-11.
4. Lees AJ, Katzenschlager R, Head J, et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57:1687-94.
5. Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64:87-93.
6. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998;13:885-94.
7. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-9.
8. Haybittle JL. The use of the Gompertz function to relate changes in life expectancy to the standardized mortality ratio. Int J Epidemiol 1998;27:885-9.
9. Tsai SP, Hardy RJ, Wen CP. The standardized mortality ratio and life expectancy. Am J Epidemiol 1992;135:824-31.
10. Lai D, Hardy RJ, Tsai SP. Statistical analysis of the standardized mortality ratio and life expectancy. Am J Epidemiol 1996;143:832- 40.
11. Pollard JH. Fun with Gompertz. Genus 1991;47:1-20.
12. Tison F, Letenneur L, Djossou F, et al. Further evidence of increased risk of mortality of Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;60:592-3.
13. Berger K, Breteler MM, Helmer C, et al. Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S24-7.
14. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival: a population-based study. Arch Neurol 2000;57:507-12.
15. Herlofson K, Lie SA, Arsland D, et al. Mortality and Parkinson disease: A community based study. Neurology 2004;62:937-42.
16. D'Amelio M, Ragonese P, Morgante L, et al. Long-term survival of Parkinson's disease. A population-based study. J Neurol 2006;253:33-7.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
18. Nobrega FT, Glattre E, Kurland LT, et al. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette JS, eds. Progress in neurogenetics. Amsterdam: Excerpta Medica, 1969:474-85.
19. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975;83:456-63.
20. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976;33:333-8.
21. Zumstein H, Siegfried J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol 1976;14:321-8.
22. Marttila RJ, Rinne UK, Siirrola T, et al. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 1977;216:147-53.
23. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-18.
24. Diamond SG, Markham CH. Mortality of parkinson patients treated with Sinemet. In: Poirier LJ, Sourkes TL, Bedard PJ, eds. Advances in neurology. New York: Raven Press, 1979:489-97.
25. Rinne UK, Sonninen V, Siirtola T, et al. Long-term responses of Parkinson's disease to levodopa therapy. J Neural Transm Suppl 1980:149-56.
26. Curtis L, Lees AJ, Stern GM, et al. Effect of L-dopa on course of Parkinson's disease. Lancet 1984;2:211-12.
27. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-82.
28. Cedarbaum JM, McDowell FH. Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems. Adv Neurol 1987;45:469-72.
29. Diamond SG, Markham CH, Hoehn MM, et al. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989;39:1187-90.
30. Ebmeier KP, Calder SA, Crawford JR, et al. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990;81:294-9.
31. Kuroda K, Tatara K, Takatorige T, et al. Effect of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand 1992;86:55-9.
32. Wermuth L, Stenager EN, Stenager E, et al. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92:55-8.
33. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-6.
34. Morens DM, Davis JW, Grandinetti A, et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46:1044-50.
35. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson disease. Arch Neurol 1997;54:260-4.
36. Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-7.
37. Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 2000;55:1785-9.
38. Guttman M, Slaughter PM, Theriault ME, et al. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 2001;57:2278-82.
39. Montastruc JL, Desboeuf K, Lapeyre-Mestre M, et al. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 2001;16:511-14.
40. Parashos SA, Maraganore DM, O'Brien PC, et al. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 2002;77:918-25.
41. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 2003;60:91-6.
42. Fall PA, Saleh A, Fredrickson M, et al. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-16.
43. Hughes TA, Ross HF, Mindham RH, et al. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-23.
44. de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005;62:1265-9.
45. Chen H, Zhang SM, Schwarzschild MA, et al. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord 2006;21:1002-7.
46. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 1988;38:1402-6.
47. Jellinger KA, Seppi K, Wenning GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;109:329-39.
48. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-18.
49. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-63.
50. Breteler MM, van den Ouweland FA, Grobbee DE, et al. A community-based study of dementia: the Rotterdam Elderly Study. Neuroepidemiology 1992;11(Suppl 1):23-8.
51. Riboli E. Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol 1992;3:783-91.
52. Maggi S, Zucchetto M, Grigoletto F, et al. The Italian Longitudinal Study on Aging (ILSA): design and methods. Aging (Milano) 1994;6:464-73.
53. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.